Data / Research funding / North Carolina / Neurogt, Inc.
Neurogt, Inc.: 6 NIH awards ($6.9M), fiscal years 2021 to 2026
Neurogt, Inc. in Chapel Hill, NC is funded under 6 NIH awards ($6.9M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- NQHRNCAD21P3
- State
- North Carolina
Awards
6 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Protein depleting pre-existing antibodies for viral gene therapy | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,276,317 | August 1, 2023 | July 31, 2026 | MCCARTY, DOUGLAS M | reporter.nih.gov |
| Development of gene therapy product for treating MPS IIIB | NIH | National Institute of Neurological Disorders and Stroke | 2024 to 2025 | $1,762,240 | September 1, 2024 | August 31, 2027 | MCCARTY, DOUGLAS M | reporter.nih.gov |
| Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS I | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $1,499,504 | September 16, 2025 | August 31, 2027 | MCCARTY, DOUGLAS M | reporter.nih.gov |
| Develop AAV9 gene replacement therapy for treating MPS I | NIH | National Institute of Neurological Disorders and Stroke | 2022 to 2023 | $702,684 | August 1, 2022 | January 31, 2025 | FU, HAIYAN | reporter.nih.gov |
| Novel AAV gene therapy for treating CNS neuropathy of MPS IIIC | NIH | National Institute of Neurological Disorders and Stroke | 2025 | $349,909 | July 8, 2025 | April 30, 2027 | FU, HAIYAN | reporter.nih.gov |
| Development of gene therapy product for treating MPS IIIB | NIH | National Institute of Neurological Disorders and Stroke | 2021 | $284,425 | April 15, 2020 | March 31, 2023 | FU, HAIYAN | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2025 | 4 | $4,125,056 | 0 | $0 |
| 2024 | 2 | $1,456,414 | 0 | $0 |
| 2023 | 2 | $630,302 | 0 | $0 |
| 2022 | 1 | $378,882 | 0 | $0 |
| 2021 | 1 | $284,425 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| Functional Target Validation for Alzheimer's Disease-Related Dementias | RFA-NS-26-034 | NIH | 93.853 | November 6, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| Clinical Trials and Ancillary Studies Conducted within NIH-Funded Clinical Trial Research Networks (UG3/UH3 - Clinical Trial Required) | PAR-27-007 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) | RFA-NS-26-001 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional) | RFA-NS-26-030 | NIH | 93.853 | November 10, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.853 | November 18, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.853 | November 18, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional) | PAR-25-052 | NIH | 93.853 | November 19, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional) | RFA-AT-25-003 | NIH | 93.853 | November 23, 2026 | $375,000 | Same assistance listing 93.853 as 5 awards here |
| Maximizing the Scientific Value of Data Generated by the Environmental Influences on Child Health Outcomes (ECHO) Program: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) | RFA-OD-27-008 | NIH | 93.853 | December 2, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.853 | December 3, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.853 | December 3, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.853 | December 4, 2026 | Not listed | Same assistance listing 93.853 as 5 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.853 | January 7, 2027 | $375,000 | Same assistance listing 93.853 as 5 awards here |
| HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed) | RFA-NS-25-023 | NIH | 93.853 | January 15, 2027 | $350,000 | Same assistance listing 93.853 as 5 awards here |
| HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required) | RFA-DA-28-011 | NIH | 93.853 | January 26, 2027 | Not listed | Same assistance listing 93.853 as 5 awards here |
| HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center (U2C Clinical Trial Not Allowed) | RFA-DA-28-012 | NIH | 93.853 | January 26, 2027 | Not listed | Same assistance listing 93.853 as 5 awards here |
| Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed) | PAR-24-268 | NIH | 93.853 | January 27, 2027 | $500,000 | Same assistance listing 93.853 as 5 awards here |
| Translational Neural Devices (R61/R33 - Clinical Trial Optional) | PAR-25-053 | NIH | 93.853 | January 28, 2027 | Not listed | Same assistance listing 93.853 as 5 awards here |
| BRAIN Initiative: Preclinical Proof of Concept for Novel Recording and Modulation Technologies in the Human CNS (R18 - Clinical Trial Not Allowed) | RFA-NS-24-031 | NIH | 93.853 | January 28, 2027 | $750,000 | Same assistance listing 93.853 as 5 awards here |
| BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System | RFA-NS-28-006 | NIH | 93.853 | January 28, 2027 | Not listed | Same assistance listing 93.853 as 5 awards here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.